Creative Biolabs has expanded its antibody portfolio to include reagents targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1, addressing a persistent need for specialized tools in human retrovirus research. The announcement, made on September 24, 2026, highlights the company's focus on supporting virology, immunology, vaccine development, and diagnostic assay development. Research antibodies that target defined viral proteins are essential for studying viral entry, epitope recognition, immune responses, and the creation of diagnostic assays. By offering antibodies against multiple retroviruses, Creative Biolabs aims to provide researchers with greater flexibility in experimental design and comparative studies.
The expansion includes an antibody against the HIV-1 gp140 protein, an uncleaved ectodomain of the viral envelope glycoprotein. This protein is a primary target for broadly neutralizing antibodies and vaccine design, making the reagent valuable for investigations into HIV-1 envelope biology, antigen recognition, and related assay development. While HIV-1 accounts for the majority of global infections, HIV-2 presents distinct clinical challenges due to its different genetic makeup and disease progression rates. Because gp36 is an HIV-2 envelope-associated antigen, antibodies targeting gp36 serve as useful research tools for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts. The availability of such reagents is critical for differentiating between these two viral types and for advancing research into HIV-2-specific diagnostics and therapies.
Beyond HIV, the human T-cell lymphotropic virus type 1 (HTLV-1) represents another significant retroviral threat, as it is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. The HTLV-1 gag p19 protein, a viral core component, is commonly investigated in studies of viral biology, protein expression, and immune recognition. Creative Biolabs' anti-HTLV-1 gag p19 antibody is designed for research applications such as Western blot, ELISA, and immunohistochemistry, supporting investigations into HTLV-1 pathogenesis and related virology questions. This addition is particularly important given the limited treatment options for HTLV-1-associated diseases and the need for reliable research tools to study viral mechanisms.
A senior scientist at Creative Biolabs noted, "Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats. By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development." The expansion reflects a broader trend in infectious disease research toward more precise and versatile reagents that can accelerate discoveries in virology and immunology.
The implications of this portfolio expansion extend to vaccine development, where understanding antibody responses to specific viral proteins can inform immunogen design. For diagnostic assay development, the availability of well-characterized antibodies can improve the sensitivity and specificity of tests for HIV-2 and HTLV-1, which are often overlooked in regions where HIV-1 predominates. Creative Biolabs provides retrovirus-targeted antibodies and custom antibody development services for research applications in virology and infectious disease. For more information about the complete range of retrovirus-targeted antibodies and custom services, researchers can visit https://www.antibody-creativebiolabs.com/. It is important to note that these products are for research use only and are not intended for diagnostic or therapeutic procedures.
